Search jobs 04-Mar-2021 Genentech’s Actemra Becomes the First Biologic Therapy Approved by the FDA for Slowing the Rate of Decline in Pulmonary Function in Adults With Systemic Sclerosis-Associated Interstitial Lung Disease, a Rare, Debilitating Condition – Systemic sclerosis (SSc) is a rare disease that impacts up to 75,000 people in the United States – – Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung function and can be life-threatening – – In a global study, Actemra reduced the rate of progressive loss of lung function in people with SSc-ILD compared to placebo – – The U.S. Food and Drug Administration previously granted Priority Review designation to Actemra for the treatment of SSc-ILD –